|
|
|
|
Target Discovered That Could Ease Spinal Muscular Atrophy Symptoms
Also Included In: Genetics; Biology / Biochemistry; Muscular Dystrophy / ALS email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public: 5 (1 votes) Health Professional:...
|
|
|
Exploring Ethical Challenges Health Professionals Face While Caring For Children Affected By Life-Threatening
Pediatrics / Children's Health News Main Category: Pediatrics / Children's Health Also Included In: Psychology / Psychiatry; Neurology / Neuroscience; Muscular Dystrophy / ALS email to a friend printer friendly view / write...
|
|
|
Start-up testing gene-based treatment for arthritis
CHAPEL HILL, NCAttorney Sheila Mikhail is once again showing that raising venture money is not the only way to get a promising start up going, even in the money-hungry field of biotech.Not only that, sometimes, all thats necessary to...
|
|
|
Possible Mechanism Of Muscle Denervation In Emery-Dreifuss Muscular Dystrophy
Muscular Dystrophy / ALS News Main Category: Muscular Dystrophy / ALS Also Included In: Genetics; Neurology / Neuroscience email to a friend printer friendly view / write opinions rate article Current Article Ratings:...
|
|
|
Potential Therapy For Congenital Muscular Dystrophy
Current research suggests laminin, a protein that helps cells stick together, may lead to enhanced muscle repair in muscular dystrophy.The related report by Rooney et al, 'Laminin-111 restores regenerative capacity in a mouse model...
|
|
|
Potential Therapy For Congenital Muscular Dystrophy, University of Nevada School of Medicine Study
ScienceDaily (Dec.Potential Therapy For Congenital Muscular Dystrophy, University of Nevada School of Medicine Study.
|
|
|
Potential therapy for congenital muscular dystrophy
Reno, Nevada Current research suggests laminin, a protein that helps cells stick together, may lead to enhanced muscle repair in muscular dystrophy.The related report by Rooney et al, 'Laminin-111 restores regenerative capacity in a...
|
|
|
Medical News: AVI BioPharma Announces FDA Clears IND Applications For Clinical Trials Of RNA Therapeutic Agent
Regulatory Affairs / Drug Approvals News Main Category: Regulatory Affairs / Drug Approvals Also Included In: Infectious Diseases / Bacteria / Viruses email to a friend printer friendly view / write opinions rate article Current Article...
|
|
|
AVI BioPharma, Inc. (AVII) Announces FDA Clearance of IND Applications for Clinical Trials of RNA Therapeutic
- (NASDAQ: AVII), a developer of RNA-based drugs, announced that it learned earlier today that it has received verbal clearance from the United States Food and Drug Administration (FDA) for the Investigational New Drug (IND) applications...
|
|
|
Parent Project Muscular Dystrophy Awards First End Duchenne Grant
Brown University to Receive Grant Promoting Translational Research in Rare Muscular Disease MIDDLETOWN, Ohio, Dec.23 /PRNewswire-USNewswire/ -- Patricia A. Furlong, Founding President and CEO of Parent Project Muscular ...
|
|
|
AVI BioPharma Announces FDA Clearance of IND Applications for Clinical Trials of RNA Therapeutic Agents for Tr
AVI BioPharma, Inc.(NASDAQ: AVII), a developer of RNA-based drugs, announced that it learned earlier today that it has received verbal clearance from the United States Food and Drug Administration (FDA) for the Investigational New Drug ...
|
|
|
Parent Project Muscular Dystrophy Awards First End Duchenne Grant
Brown University to Receive Grant Promoting Translational Research in Rare Muscular Disease MIDDLETOWN, Ohio, Dec.23 /PRNewswire-USNewswire/ -- Patricia A. Furlong, Founding President and CEO of Parent Project Muscular ...
|
|
|
Parent Project Muscular Dystrophy Awards First End Duchenne Grant
Brown University to Receive Grant Promoting Translational Research in Rare Muscular Disease MIDDLETOWN, Ohio, Dec.23 /PRNewswire-USNewswire/ -- Patricia A. Furlong, Founding President and CEO of Parent Project Muscular ...
|
|
|
Parent Project Muscular Dystrophy Awards First End Duchenne Grant
MIDDLETOWN, Ohio, Dec.23 /PRNewswire-USNewswire/ -- Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a...
|
|
|
AVI BioPharma Announces FDA Clearance of IND Applications for Clinical Trials of RNA Therapeutic Agents for Tr
AVI BioPharma, Inc.(NASDAQ: AVII), a developer of RNA-based drugs, announced that it learned earlier today that it has received verbal clearance from the United States Food and Drug Administration (FDA) for the Investigational New Drug ...
|
|
|
AVI BioPharma Announces FDA Clearance of IND Applications for Clinical Trials of RNA Therapeutic Agents for Tr
AVI BioPharma, Inc.(NASDAQ: AVII), a developer of RNA-based drugs, announced that it learned earlier today that it has received verbal clearance from the United States Food and Drug Administration (FDA) for the Investigational New Drug ...
|
|
|
AVI BioPharma Announces FDA Clearance of IND Applications for
AVI BioPharma, Inc.(NASDAQ: AVII), a developer of RNA-based drugs, announced that it learned earlier today that it has received verbal clearance from the United States Food and Drug Administration (FDA) for the Investigational New Drug ...
|
|
|
AVI BioPharma Announces FDA Clearance of IND Applications for Clinical Trials of RNA Therapeutic Agents for Tr
-- AVI BioPharma, Inc.(NasdaqGM:AVII - News), a developer of RNA-based drugs, announced that it learned earlier today that it has received verbal clearance from the United States Food and Drug Administration (FDA) for the Investigational...
|
|
|
AVI BioPharma Announces FDA Clearance of IND Applications for Clinical Trials of RNA Therapeutic Agents for Tr
(MARKET WIRE via COMTEX) -- AVI BioPharma, Inc.(AVII:AVIINews , chart , profile , more Last: Delayed quote data Analyst Create alert Insider Discuss Financials Sponsored by: , , ) , a developer of RNA-based drugs, announced that it...
|
|
|
Court: No obligation for company to give teen drug
WASHINGTON (AP) - A pharmaceutical company does not have to provide an experimental drug to a Minnesota teen who is terminally ill with a rare form of muscular dystrophy, a federal appeals court ruled Tuesday in reversing a lower court...
|
|
|
Federal appeals court says that no obligation for company to give teen drug
WASHINGTON - A federal appeals court says that a pharmaceutical company does not have to provide an experimental drug to a Minnesota teen who is terminally ill with a rare form of muscular dystrophy.The ruling reversing a lower...
|
|
|
Federal appeals court says that no obligation for company to give teen drug
WASHINGTON - A federal appeals court says that a pharmaceutical company does not have to provide an experimental drug to a Minnesota teen who is terminally ill with a rare form of muscular dystrophy.The ruling reversing a lower...
|
|
|
Federal appeals court says that no obligation for company to give teen drug
WASHINGTON - A federal appeals court says that a pharmaceutical company does not have to provide an experimental drug to a Minnesota teen who is terminally ill with a rare form of muscular dystrophy.The ruling reversing a lower...
|
|
|
Federal court says that no obligation for company to give teen drug
WASHINGTON - A federal appeals court says that a pharmaceutical company does not have to provide an experimental drug to a Minnesota teen who is terminally ill with a rare form of muscular dystrophy.The ruling reversing a lower...
|
|
|
Gimv Invests EUR 4.25 million in Dutch Biotech Company Prosensa
Belgium company Gimv has invested EUR 4.25 million in the series B funding round of Dutch biotech company Prosensa.Together with AGF (France), Gimv acted as a co-lead investor in a total financing round of EUR 18 million. The existing...
|
